Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 9, 2005, Pages 1128-1132

  Brody, Alan S ^a   Sucharew, Heidi ^b   Campbell, Jonathan D ^b   Millard, Steven P ^b   Molina, Paul L ^b   Klein, Jeffrey S ^b   Quan, Joanne ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

Children; Computerized tomography X ray; Forced expiratory volume; Pulmonary function tests; Surrogate endpoint

Indexed keywords

ACCURACY; ARTICLE; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LONGITUDINAL STUDY; LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POISSON DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; REPRODUCIBILITY OF RESULTS; RESPIRATION DISORDERS; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 30344460714     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200407-989OC     Document Type: Article

References (35)

1. U.S. Food and Drug Administration. New initiatives to speed access to new drugs. Rockville, MD: U.S. Food and Drug Administration; 1992.
2. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 2001;22:485-502.
3. National Institutes of Health. Workshop on surrogate markers for CF. Bethesda, MD: National Institutes of Health; 1997.
4. Brody A, Klein J, Molina P, Campbell J, Millard S, Quan J. High-resolution CT correlates with the number of exacerbations in young children with CF. Pediatr Pulmonol 2003;36(S25):318-319.
5. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
6. American Thoracic Society. ATS statement: Snowbird workshop on standardization of spirometry. Am Rev Respir Dis 1979;119:831-838.
7. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88.
8. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125:509-521.
9. Brody AS. Early morphologic changes in the lungs of asymptomatic infants and young children with cystic fibrosis. J Pediatr 2004;144:145-146.
10. Brody AS, Kosorok MR, Li Z, Broderick LS, Foster JL, Laxova A, Bandla H, Farrell PM. Reproducibility of a scoring system for CT scanning in cystic fibrosis. Pediatr Pulmonol 2004;2004:299.
11. Zar J. Biostatistical analysis, 4th ed. Englewood, NJ: Prentice-Hall; 1999.
12. Everitt B, Rabe-Hesketh S. Analyzing medical data using S-PLUS. New York: Springer; 2001.
13. Venables WN, Ripley BD. Modern applied statistics with S-PLUS. New York: Springer; 1999.
14. Draper N, Smith H. Applied regression analysis, 3rd ed. New York: Wiley; 1998.
15. Cystic Fibrosis Foundation. Patient registry: 2002 annual report. Bethesda, MD: Cystic Fibrosis Foundation; 2003.
16. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 1994;124:177-192.
17. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144:154-161.
18. Helbich TH, Heinz-Peer G, Fleischmann D, Wojnarowski C, Wunderbaldinger P, Huber S, Eichler I, Herold CJ. Evolution of CT findings in patients with cystic fibrosis. AJR Am J Roentgenol 1999;173:81-88.
19. de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R, Pare PD, Tiddens HA. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23:93-97.
20. Goris ML, Zhu HJ, Blankenberg F, Chan F, Robinson TE. An automated approach to quantitative air trapping measurements in mild cystic fibrosis. Chest 2003;123:1655-1663.
21. Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol 1997;169:375-380.
22. Brody AS, Molina PL, Klein JS, Rothman BS, Ramagopal M, Swartz DR. High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. Pediatr Radiol 1999;29:731-735.
23. Robinson TEKK, Newaskar M, Bhise P, Mishra N, Blankenberg FG, Northway WH, Leung AN, Moss RB. Spirometer-triggered high-resolution computed tomography (HRCT) scores in mild and moderate to severe CF lung disease. Pediatr Pulmonol 2001(Suppl);22:378.
24. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
25. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: part I. Circulation 2002;106:746-751.
26. Smith JJ, Sorensen AG, Thrall JH. Biomarkers in imaging: realizing radiology's future. Radiology 2003;227:633-638.
27. Temple RJ. A regulator authority's opinion about surrogate endpoints. In: Nimmo WS, editor. Clinical measurements on drug evaluation. New York: Wiley; 1995.
28. Kang EY, Miller RR, Muller NL. Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens. Radiology 1995;195:649-654.
29. Nathanson I, Conboy K, Murphy S, Afshani E, Kuhn JP. Ultrafast computerized tomography of the chest in cystic fibrosis: a new scoring system. Pediatr Pulmonol 1991;11:81-86.
30. Helbich TH, Heinz-Peer G, Eichler I, Wunderbaldinger P, Gotz M, Wojnarowski C, Brasch RC, Herold CJ. Cystic fibrosis: CT assessment of lung involvement in children and adults. Radiology 1999;213:537-544.
31. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-1256.
32. MacLusky ILH. Cystic fibrosis. In: Chernick V, Boat TF, Kending EL Jr, editors. Kendig's disorders of the respiratory tract in children. Philadelphia: WB Saunders; 1998. p. 838-882.
33. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
34. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
35. Lucaya J, Piqueras J, Garcia-Pena P, Enriquez G, Garcia-Macias M, Sotil J. Low-dose high-resolution CT of the chest in children and young adults: dose, cooperation, artifact incidence, and image quality. AJR Am J Roentgenol 2000;175:985-992.